相关实验视频
Updated: Jul 21, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
梅萨拉颗粒可促进轻度至中度性结肠炎患者的疾病清除
Wolfgang Kruis1, Silke Meszaros2, Sarah Wehrum2
1Emeritus Head of Gastroenterology, Evangelisches Krankenhaus Kalk gGmbH, Pulheim-Freimersdorf, Germany.
在用梅萨拉颗粒治疗的性结肠炎 (UC) 患者中,可以实现疾病清除,定义为临床,内镜和组织学缓解. 每日3.0克梅萨拉颗粒剂的剂量似乎是达到这一严格治疗目标的最佳剂量.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 性结肠炎 (UC) 治疗目标已经向更严格的参数发展.
- 疾病清除,即临床,内镜和组织学缓解的复合,是UC管理的最终终点.
研究的目的:
- 评估在接受不同剂量的梅萨拉颗粒诱导治疗的轻度至中度UC患者的疾病清除率.
- 确定最佳的梅萨拉颗粒剂量,以实现疾病清除.
主要方法:
- 一项对四项随机,主动控制的第三期临床试验的后期分析,涉及860名患有轻度至中度UC的患者.
- 患者接受了为期8周的诱导疗法,每天服用1.5g,3.0g或4.5g的梅萨拉颗粒.
- 使用严格的临床,内镜和组织学缓解标准计算疾病清除率.
主要成果:
- 总体而言,20.0%的患者实现了疾病清除. 根据剂量变化的比率:13.1% (1.5克),21.8% (3.0克) 和18.9% (4.5克).
- 在中度UC患者中,整体疾病清除率为16.8%,剂量特定率为7.1% (1.5g),18.8% (3.0g) 和16.2% (4.5g).
- 每天3.0克的剂量显示出在总人口中疾病清除率最高.
结论:
- 梅萨拉颗粒可以在临床上显著比例的轻度至中度UC患者中实现疾病清除.
- 每日3.0克的梅萨拉颗粒剂似乎是实现疾病清除的最佳剂量.
- 实现疾病清除可能预测性结肠炎管理的改善长期结果.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...